Burning Rock Announces Preliminary Fourth Quarter and Full Year 2020 Results and Schedules Earnings Release on March 11, 2021

Rhea-AI Summary

Burning Rock Biotech Limited (NASDAQ: BNR) announced plans to release its unaudited fourth quarter and full year 2020 financial results before markets open on March 11, 2021. Following the results, a conference call will be held at 8:00 a.m. ET to discuss financial outcomes. The company focuses on next-generation sequencing for precision oncology, holding a leading market share in China with over 273,000 tests completed. Investors can access the earnings release on the company’s investor relations website.

Positive

• Leading market share in China for NGS-based therapy selection testing.
• Over 273,000 tissue and liquid-based tests completed cumulatively.
• Transition from R&D to clinical validation in cancer early detection.

Negative

• None.

GUANGZHOU, China, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited fourth quarter and full year 2020 financial results before the U.S. market opens on March 11, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET on (9:00 p.m. Hong Kong time) the same day to discuss its financial results for the fourth quarter and full year 2020.

Details of the conference call are as follows:

International:	+65 67135090
U.S.:	+1 8456750437
U.K.:	+44 2036214779
Hong Kong:	+852 30186771
China Mobile:	4006208038
China Landline:	8008190121
Conference ID:	5266945

A replay of the fourth quarter and full year 2020 financial results conference call will be available for one week (dial-in number: +61 2 8199 0299; same conference ID as shown above).

Please visit the company’s investor relations website at https://ir.brbiotech.com/news-events/news-releases on March 11, 2021 to view the earnings release prior to the conference call.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: www.brbiotech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com

FAQ

When will Burning Rock Biotech announce its Q4 and full year 2020 financial results?

Burning Rock Biotech will announce its financial results before the market opens on March 11, 2021.

What time is the conference call for Burning Rock Biotech's financial results?

The conference call will be held at 8:00 a.m. ET on March 11, 2021.

How many tests has Burning Rock Biotech completed?

The company has completed over 273,000 tissue and liquid-based tests cumulatively.

What technology does Burning Rock Biotech focus on?

Burning Rock focuses on next-generation sequencing technology in the field of precision oncology.